Conventional thrombolytic drugs for vascular blockage such as tissue plasminogen activator
(tPA) are challenged by the low bioavailability, off-target side effects and limited penetration …

In previously published studies, intra-arterial (ia), but not intravenous (iv) delivery of
recombinant tissue-type plasminogen activator (rtPA) immobilized on the surface of …

Thrombotic occlusion of the coronary artery, which triggers acute myocardial infarction, is
one of the major causes of death in the USA. Currently, arterial occlusions are treated with …

Platelet adhesion, activation and fibrinogen-mediated aggregation are primary events in
vascular thrombosis and occlusion. An injectable delivery system that can carry …

Treatment of bleeding disorders using transfusion of donor-derived platelets faces logistical
challenges due to their limited availability, high risk of contamination, and short (5 to 7 days) …

Thrombosis, a critical event in blood vessels, not only is associated with myocardial
infarction and stroke, but also accounts for considerable morbidity and mortality …

The safe administration of thrombolytic agents is a challenge for the treatment of acute
thrombosis. Lipid‐based nanoparticle drug delivery technologies present opportunities to …

Streptokinase is one of the most commonly used thrombolytic agents for the treatment of
thromboembolism. Short half-life of the streptokinase requires administration of higher dose …

Severe hemorrhage associated with trauma, surgery, and congenital or drug-induced
coagulopathies can be life-threatening and requires rapid hemostatic management via …

Platelet-mimetic synthetic hemostats are highly attractive in transfusion medicine. To this
end, past research reports have described particles that either amplify platelet aggregation …